What if you invested $1000 in CTLT on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
About Catalent, Inc.
Visit Website ↗Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) that partners with pharmaceutical, biotech, and consumer health companies. Its mission is to develop, manufacture, and supply products that help people live better and healthier lives.
Key Business Segments
Oral and Specialty Delivery
Provides advanced oral and other dosage form development, manufacturing, and packaging services for various drug products.
Biologics and Sterile Filling
Offers development and manufacturing services for biologics, sterile injectables, and advanced therapeutics, including gene and cell therapies.
Clinical Supply Services
Provides comprehensive clinical supply services, including clinical trial material manufacturing, packaging, and logistics.
Key Innovations
- ✓Pioneered the patented rotary die softgel process for drug encapsulation, revolutionizing medicine delivery.
- ✓Developed advanced drug delivery technologies such as Zydis® fast-dissolve tablets and Liqui-Gels® preparations.
Historical Milestones
R.P. Scherer revolutionizes medicine delivery with his patented rotary die softgel process.
Catalent is formed as a spin-off from Cardinal Health's Pharmaceutical Technologies and Services (PTS) segment.
Catalent becomes a public company via an initial public offering (IPO) on the New York Stock Exchange.
Catalent is acquired by Novo Holdings A/S, with a significant portion of its manufacturing facilities later acquired by Novo Nordisk.